Alcami, a U.S.-based CDMO, has signed a master laboratory services agreement with Novavax, a biotechnology company developing next-generation vaccines for infectious diseases. Under the agreement, Novavax has immediately secured full-time equivalent (FTE) resources to provide analytical testing support for its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.   “The large molecule analytical support we have been engaged to provide is a testament to...